Lacto N Fucopentaose Ii Suppliers USA
Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
Product | Description | |
---|---|---|
Lacto-N-fucopentaose II Quick inquiry Where to buy Suppliers range | It is a human milk oilgosaccharide that can be associated with some gastrointestinal tumors. Synonyms: LNFP II; Lewisa antigen; Lewis A antigen; b-D-Gal-(1?3)-(a-L-Fuc-[1?4])-b-D-GlcNAc-(1?3)-b-D-Gal-(1?4)-D-Glc; β-D-Galp-(1?3)-[α-L-Fucp-(1?4)]-β-D-GlcpNAc-(1?3)-β-D-Galp-(1?4)-D-Glcp; Lewis-a pentasaccharide; LNF II; Lacto-N-fucopentaose-2; Lea penta. Grades: ≥95%. CAS No. 21973-23-9. Molecular formula: C32H55NO25. Mole weight: 853.77. | |
Lacto-N-fucopentaose II Quick inquiry Where to buy Suppliers range | Lacto-N-fucopentaose II. Group: Biobased Products. Alternative Names: Galβ1, 3GlcNAc(α1, 2Fuc)b1, 3Galβ1, 4Glc. Grades: 95%. CAS No. 21973-23-9. Product ID: BBC21973239. Molecular formula: C32H55NO25. Mole weight: 853.77. IUPAC Name: N-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide. Density: 1.71±0.1 g/ml. SMILES: C[C@H]1[C@H] ([C@H] ([C@@H] ([C@@H] (O1)O[C@@H]2[C@H] (O[C@H] ([C@@H] ([C@H]2O[C@H]3[C@@H] ([C@H] ([C@H] ([C@H] (O3)CO)O)O)O)NC (=O)C)O[C@H]4[C@H] ([C@H] (O[C@H] ([C@@H]4O)O[C@H] ([C@@H] (CO)O)[C@@H] ([C@H] (C=O)O)O)CO)O)CO)O)O)O. | |
Lacto-N-fucopentaose II-APD-HSA Quick inquiry Where to buy Suppliers range | ||
Lacto-N-fucopentaose II-APD-KLH Quick inquiry Where to buy Suppliers range | Lacto-N-fucopentaose II-APD-KLH is an extraordinary bioactive compound prevalent in the biomedical sector, exhibitionizes immense promise for research across diverse diseases through its remarkable affinities for selective receptors, namely Fucosyltransferase and Galectins. It has garnered extensive utilization within research domains aiming to unravel the intricacies of cancer, inflammation and immune-related maladies, as well as devising innovative strategies for their effective research. | |
Lacto-N-fucopentaose II-BSA Quick inquiry Where to buy Suppliers range | ||
Lacto-N-fucopentaose II-BSA (LNFP II-BSA) (3 atom spacer) Quick inquiry Where to buy Suppliers range | Lacto-N-fucopentaose II-BSA (LNFP II-BSA) (3 atom spacer), a biomedicine product designed for unravelling the mysteries of glycan-protein interactions. Widely employed for diagnosis of Helicobacter pylori (H. pylori) in serum samples of infected individuals, its applications extend beyond the laboratory. Studies have revealed its crucial role in illuminating the intricacies of carbohydrate-mediated ailments such as cancer and inflammation. | |
Lacto-N-fucopentaose II-GEL Quick inquiry Where to buy Suppliers range | Lacto-N-fucopentaose II-GEL is a paramount biomedical compound, serving as a tool for deciphering intricate complexities attributed to the functions and interplays of carbohydrates within cellular systems. By facilitating the detection of lectins, glycosylation analysis and exploration of carbohydrate impacts on disease advancement, this product assumes a pivotal significance. Its indispensability lies in unraveling the pathogenesis of specific ailments and forging prospects for prospective researchs. | |
Lacto-N-fucopentaose III Quick inquiry Where to buy Suppliers range | It is a human milk oilgosaccharide that can inhibit the adherence of pathogens to the intestinal epithelium. Synonyms: LNFP III; Lewis X antigen; Gal-b-1,4-(Fuc-a-1,3)-GlcNAc-b-1,3-D-Gal-b-1,4-Glc; Lex-lactosel; Lewis-X pentasaccharide; β-D-Galp-(1?4)-[α-L-Fucp-(1?3)]-β-D-GlcpNAc-(1?3)-β-D-Galp-(1?4)-D-Glcp; O-6-deoxy-alpha-L-galactopyranosyl-(1->3)-O-[beta-D-galactopyranosyl-(1->4)]-O-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->3)-O-beta-D-galactopyranosyl-(1->4)-D-Glucopyranose; 6-Deoxy-α-L-galactopyranosyl-(1->3)-[β-D-galactopyranosyl-(1->4)]-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1->3)-β-D-galactopyranosyl-(1->4)-D-glucose; Lacto-N-neofucopentaose II. Grades: ≥95%. CAS No. 25541-09-7. Molecular formula: C32H55NO25. Mole weight: 853.77. | |
Lacto-N-fucopentaose III-APD-HSA Quick inquiry Where to buy Suppliers range | ||
Lacto-N-fucopentaose III-BSA Quick inquiry Where to buy Suppliers range | ||
Lacto-N-fucopentaose III-BSA (LNFP III-BSA) (3 atom spacer) Quick inquiry Where to buy Suppliers range | Lacto-N-fucopentaose III-BSA (LNFP III-BSA) (3 atom spacer) is an astounding specialized biomedical wonder, harbors immense value for the scientific realm. This groundbreaking product unravels the intricacies behind carbohydrate-protein interactions, facilitating a comprehensive understanding of this enigmatic domain. A conjugate brimming with potential, LNFP III-BSA amalgamates the captivating carbohydrate structure of Lacto-N-fucopentaose III with the mighty Bovine Serum Albumin (BSA) and an elegant 3 atom spacer. Its importance transcends mere investigation, offering invaluable insights into drug development and the intricate pathology of diseases intricately linked to carbohydrate recognition. Prepare to embark on an academic odyssey like no other, courtesy of LNFP III-BSA. | |
Lacto-N-fucopentaose III-GEL Quick inquiry Where to buy Suppliers range | Lacto-N-fucopentaose III-GEL is an advanced biomedical product engineered to precisely target and study diverse malignancies, including breast, ovarian and colon cancers. This exceptional gel conjugate seamlessly integrates the distinctive attributes of Lacto-N-fucopentaose III is a specific carbohydrate molecule, with a sophisticated gel matrix, thereby ensuring optimal drug administration and localized research. Through its selective adherence to cancerous cells, this compound holds remarkable prospects for individualized therapy, ultimately enhancing patient prognosis substantially. |